UPDATE: Cleveland BioLabs Provides Update on Barda Development Proposal

By: Benzinga
Cleveland BioLabs (Nasdaq: CBLI ) today announced that the Biomedical Advanced Research and Development Authority ("BARDA") has terminated negotiations related to the Company's proposal for further development of Entolimod as a medical radiation countermeasure, noting that all such negotiations are subject to the availability of funds.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.